Circ_0092367 Inhibits EMT and Gemcitabine Resistance in Pancreatic Cancer via Regulating the miR-1206/ESRP1 Axis

Gemcitabine is the first-line treatment for patients with pancreatic cancer (PC), yet most patients develop resistance to gemcitabine. Recent studies showed that circular RNAs (circRNAs) have important regulatory roles in PC progression and chemoresistance. In this study, the ability of circRNA circ...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Shuo, Wang, Min, Zhang, Hang, Guo, Xingjun, Qin, Renyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8622583/
https://www.ncbi.nlm.nih.gov/pubmed/34828307
http://dx.doi.org/10.3390/genes12111701

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8622583/
https://www.ncbi.nlm.nih.gov/pubmed/34828307
http://dx.doi.org/10.3390/genes12111701

Ejemplares similares